Clinical trials: Glucagon
Steatosis of Liver
Liver Fat and Glucagon Resistance
One in four adults worldwide have too much fat stored in the liver which is known as metabolic associated steatotic liver disease (MASLD). This was previously known as non- alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT06154096
- Testing
- Acute glucagon infusion
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Type 1 Diabetes Mellitus
Glucagon Counterregulation in Type 1 Diabetes
The purpose of this study is to find out whether the combination of insulin and pramlintide is better than insulin alone at helping the pancreas release glucagon in response to a low blood sugar episode.
- Trial name
- NCT03547427
- Testing
- Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Virginia
Intestinal Failure, Short Bowel Syndrome
Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure
This protocol outlines a randomized,open label trial examining the safety, pharmacology and efficacy of Glucagon like peptide 2 (GLP-2) in infants and children with intestinal failure.
- Trial name
- GLP-2-01 (NCT01573286)
- Testing
- Glucagon-Like Peptide 2, Glucagon like peptide-2
- Where
- 4 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Alberta Children's Hospital
Type 1 Diabetes
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases fasting, postprandial and the overall mean glucose concentrations.
- Trial name
- NCT01722266
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Type 1 Diabetes
Combination GRA and SGLT-2i Treatment in Type 1 Diabetes
A pilot study for individuals with Type 1 Diabetes who are willing to add an SGLT-2i (Sodium-Glucose Cotransporter-2 Inhibitor) in combination with placebo or a GRA (Glucagon Receptor Antagonist) to their current diabetes…
- Trial name
- NCT04545411
- Testing
- Dapagliflozin 10 MG [Farxiga], REMD-477
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
This is a 32-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and the active comparator in patients with type 2 diabetes…
- Trial name
- NCT06739044
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 1 Diabetes
Liraglutide in Adolescents With Type 1 Diabetes
The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses in adolescents with Type…
- Trial name
- NCT02516657
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University at Buffalo
Type 2 Diabetes, Obesity
Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes
The purpose of this study is to see how hormones that control blood sugar change in response to two different weight loss surgeries (gastric bypass and gastric banding).
- Conditions
- Type 2 Diabetes, Obesity, Bariatric Surgery
- Trial name
- NCT01153438
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Type 1 Diabetes
Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes
In the unfortunate case of severe hypoglycaemia, glucagon is the first-line treatment because of its potent and rapid action starting as fast as 5 minutes after subcutaneous or intramuscular injection.
- Trial name
- NCT01828125
- Testing
- Hypoglycaemic hyperinsulinemic clamp, Glucagon
- Where
- Canada
- Sponsor
- Institut de Recherches Cliniques de Montreal
Breast Cancer (Early Breast Cancer), Obesity
Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer
This study will assess whether women with obesity and early estrogen receptor-positive breast cancer can complete 26 weeks of semaglutide treatment while continuing their prescribed hormone therapy for breast cancer.
- Trial name
- WISPER (NCT07909889)
- Testing
- Semaglutide (Wegovy®)
- Where
- 2 sites in Denmark
- Volunteers
- 32 people
- Sponsor
- Aarhus University Hospital
Glucose, High Blood
Hydration to Optimize Metabolism
This study evaluates hydration (1.5 L of water daily during 1 year) in the lowering of blood glucose concentration in adults with signs of dehydration (elevated levels of the vasopressin marker copeptin and high urine…
- Trial name
- H2O-metabolism (NCT03422848)
- Testing
- Water, general life style advice
- Where
- Sweden
- Volunteers
- 797 people, healthy volunteers welcome
- Sponsor
- Region Skane
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate…
- Trial name
- NCT03216226
- Testing
- dasiglucagon, GlucaGen
- Where
- 7 sites in United States, Austria and 2 more
- Volunteers
- 112 people
- Sponsor
- Zealand Pharma
Post-bariatric Hypoglycemia
Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
To assess the efficacy of a closed loop glucagon system to prevent and treat hypoglycemia occurring in patients with Post-Bariatric Hypoglycemia (PBH) in response to meals and exercise.
- Trial name
- NCT03255629
- Testing
- glucagon, Closed loop glucagon pump
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Joslin Diabetes Center
Healthy Volunteers Recruited From the General Population
Rapid Versus Slow Ingestion of Mixed Meal: Influence on Islet and Incretin Hormone Secretion in Healthy Volunteers
To test the influence of rapid versus slow ingestion of a mixed meal on insulin and incretin hormone secretion in healthy volunteers
- Trial name
- NCT01779622
- Testing
- Mixed meal
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lund University
Diabetes Mellitus, Type 2
Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
Mortality due to cardiovascular problems is increased by having Diabetes Mellitus type 2 (DM2), related to the time of evolution and glucose levels or if alterations in blood pressure coexist.
- Trial name
- NCT03444142
- Testing
- Exenatide LAR, Dulaglutide
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara
Metabolic Syndrome, Diabetes
Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge
The investigators previously characterized a phenotype with non-suppressed glucagon at 120 minutes after standardized oral glucose load.
- Trial name
- NCT03061227
- Testing
- Intravenous glucagon, Intravenous saline
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Obesity/Therapy
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults.
- Trial name
- PLASTIC (NCT07021937)
- Testing
- Semaglutide 1.7mg subcutaneous
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
Obesity
Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation
Longitudinal studies show there is a steep increase in weight regain in the first 3-4 months after stopping GLP-1 receptor agonist medications (GLP-1s) and most patients regain most of their weight within a year.
- Trial name
- NCT06273163
- Testing
- Medically tailored meals, Noom®, Usual care
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Texas Southwestern Medical Center
Obesity, Overweight
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.
- Trial name
- NCT07908316
- Testing
- Maridebart cafraglutide
- Where
- 9 sites in United States
- Volunteers
- 180 people
- Sponsor
- Amgen